G1G Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.30 |
| 52 Week High | AU$0.62 |
| 52 Week Low | AU$0.16 |
| Beta | 0.91 |
| 1 Month Change | -18.68% |
| 3 Month Change | -26.37% |
| 1 Year Change | -43.08% |
| 3 Year Change | -81.21% |
| 5 Year Change | -94.36% |
| Change since IPO | -95.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 3.0% |
| 1Y | -43.1% | -14.7% | 19.3% |
Return vs Industry: G1G underperformed the German Pharmaceuticals industry which returned -16.4% over the past year.
Return vs Market: G1G underperformed the German Market which returned 18.5% over the past year.
Price Volatility
| G1G volatility | |
|---|---|
| G1G Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: G1G has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: G1G's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| G1G fundamental statistics | |
|---|---|
| Market cap | €3.55m |
| Earnings (TTM) | -€22.24m |
| Revenue (TTM) | €57.74k |
61.5x
P/S Ratio-0.2x
P/E RatioIs G1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1G income statement (TTM) | |
|---|---|
| Revenue | AU$94.95k |
| Cost of Revenue | AU$328.89k |
| Gross Profit | -AU$233.93k |
| Other Expenses | AU$36.33m |
| Earnings | -AU$36.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | -246.37% |
| Net Profit Margin | -38,513.04% |
| Debt/Equity Ratio | -135.5% |
How did G1G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/18 18:26 |
| End of Day Share Price | 2025/02/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zelira Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan Hampton | Hannam & Partners (Advisory) LLP |